Cancer Research UK and the Greater Manchester Health and Social Care Partnership has produced a report suggesting a new system for reimbursement of cancer drugs by the NHS. The report suggests that paying for cancer drugs based on how well they work in practice could help patients get new treatments faster.

This new flexible system, known as outcome-based payment (OBP), would mean a drug’s price could be adjusted based on how well it works for patients in the NHS. The NHS would pay a pharmaceutical company less for a medicine that doesn’t work as well as expected, and more for a medicine that works better than expected.

Read more about the OBP system in PharmaTimes here

Read the Cancer Research UK executive summary hereR